Cytodyn Inc (CYDY)

[gestalt2]

I would think your concern is possible, but not probable. there have been too many patients injected that show a significant viral load drop. the thought that pro 140 will fail in adjunct would mean that 7-8 patients of the 15 actually being injected do not respond. It is my understanding that the past non-responders were not the right tropism and that we have a much improved screening process to make sure that does not happen. your concern could be real, but i sure would be surprised if that does happen. also, i think we are more interested in gathering a large data set and that will come from the mono trial. maybe it would make sense for the 30 enrollment for adjunct take as long as possible so there is no small sample set confusion issues?